{"id":166249,"date":"2026-09-14T20:39:31","date_gmt":"2026-09-14T20:39:31","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/166249\/"},"modified":"2026-09-14T20:39:31","modified_gmt":"2026-09-14T20:39:31","slug":"ozempic-owner-slims-down-its-name","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/166249\/","title":{"rendered":"Ozempic owner slims down its name"},"content":{"rendered":"<p>            <img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/09\/gettyimages-1739574189.jpeg\" alt=\"As the patent on semaglutide expires, Danish pharmaceutical manufacturer Novo faces increased comptetition. \" height=\"720\" width=\"1080\"\/><\/p>\n<p>&#13;<br \/>\n                    As the patent on semaglutide expires, Danish pharmaceutical manufacturer Novo faces increased comptetition. &#13;\n                <\/p>\n<p>Novo Nordisk will shorten its name for day-to-day use to just Novo in a bid to become more recognisable in its obesity market war with Eli Lilly. <\/p>\n<p>The drugmaker is also tweaking its logo, shifting its trademark bull to look to the right, it said Monday. The change comes as Lilly also increasingly leans on a single-name identity, dropping the word \u201cEli\u201d from its marketing materials. Like Lilly, Novo will retain its full name as a legal global company name. <\/p>\n<p>Chief Executive Officer Mike Doustdar is pushing Novo to become leaner and more competitive as the Danish company tries to wrest back a larger share of the obesity market it pioneered from Lilly. The brand is \u201cstrategically important\u201d, Doustdar said. <\/p>\n<p>For Novo, stripping \u201cNordisk\u201d from the everyday name removes a link to the company\u2019s history. The drugmaker was founded as Nordisk Insulinlaboratorium in 1923, bringing the newly-discovered technology for producing insulin to Denmark. Former employees founded the rival Novo branch two years later, and the two merged in 1989. <\/p>\n<p>Doustdar will present the new brand identity to employees tomorrow. Next week, he will face investors at the company\u2019s annual capital markets day.<\/p>\n<p>\u201cA new name, logo, and slogan must be accompanied by a true strategic change,\u201d Evan David Seigerman, an analyst at BMO Capital Markets, wrote in a note. Next week\u2019s meeting \u201cmust bring substance and strategic direction to support a sustainable organisation into the 2030s and beyond.\u201d <\/p>\n<p>Newsletter<\/p>\n<p>            Weekdays\n        <\/p>\n<p>SA Money Daily<\/p>\n<p>The biggest business, economic and market news of the day.<\/p>\n<p>        <a class=\"button\" id=\"subscribe-button\" data-event-name=\"newsletter_subscribe\" href=\"http:\/\/www.news24.com\/individualnewsletter\/signup\/3989?returnurl=https%3a%2f%2fwww.news24.com%2findividualnewsletter%2fsignup%2f3989%3freturnurl%3dhttps%253a%252f%252fwww.news24.com%252fbusiness%252fcompanies%252fozempic-owner-slims-down-its-name-20260914-0463\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n            Sign up<br \/>\n        <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"&#13; As the patent on semaglutide expires, Danish pharmaceutical manufacturer Novo faces increased comptetition. &#13; Novo Nordisk will&hellip;\n","protected":false},"author":2,"featured_media":166250,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,34557,272,3102],"class_list":["post-166249","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-know","tag-novo-nordisk","tag-ozempic"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117271328821488438","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/166249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=166249"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/166249\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/166250"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=166249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=166249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=166249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}